|
Delayed
Nasdaq Stockholm
08:38:35 2026-10-29 EDT
|
5-day change | 1st Jan Change | ||
| 0.1525 SEK | -0.65% |
|
-13.84% | -46.30% |
| 08-28 | Xintela AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 06-01 | Flerie portfolio company Xintela reports positive study results for stem cell product | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 13.33M | - | - | - | - | - |
| 64.14B | |||||
| 55.53B | |||||
| 53.03B | |||||
| 45.99B | |||||
| 42.45B |
- Stock Market
- Stocks
- XINT Stock
- Charts Xintela AB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
